|
ZA811368B
(en)
|
1980-03-24 |
1982-04-28 |
Genentech Inc |
Bacterial polypedtide expression employing tryptophan promoter-operator
|
|
JPS62501537A
(ja)
*
|
1984-12-21 |
1987-06-25 |
テクニクロン・リサ−チ・パ−トナ−ズ・ワン |
リンパ球細胞を電気的に不滅化するための方法
|
|
DE3531430A1
(de)
|
1985-09-03 |
1987-03-05 |
Biotest Pharma Gmbh |
Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten
|
|
US4963489A
(en)
*
|
1987-04-14 |
1990-10-16 |
Marrow-Tech, Inc. |
Three-dimensional cell and tissue culture system
|
|
US4900322A
(en)
|
1986-09-22 |
1990-02-13 |
Adams James D |
Blood component pooling valve and kit
|
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
|
US5399493A
(en)
|
1989-06-15 |
1995-03-21 |
The Regents Of The University Of Michigan |
Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
|
|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
US5674980A
(en)
*
|
1989-12-21 |
1997-10-07 |
Biogen Inc |
Fusion protein comprising tat-derived transport moiety
|
|
US5849288A
(en)
|
1990-01-15 |
1998-12-15 |
Yeda Research And Development Co. Ltd. |
Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
|
US5843728A
(en)
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
AU781922B2
(en)
|
1991-12-17 |
2005-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5289858A
(en)
|
1991-12-18 |
1994-03-01 |
Abbott Laboratories |
System for accommodating withdrawal of liquid from a bulk supply
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
EP0903408A3
(en)
|
1992-08-21 |
2005-11-02 |
Biogen, Inc. |
Tat-derived transport polypeptide
|
|
US5580760A
(en)
|
1993-02-22 |
1996-12-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
FUSE binding protein and cDNA therefor
|
|
EP0710283A4
(en)
|
1993-07-22 |
1997-07-02 |
Merck & Co Inc |
THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
|
|
US5599705A
(en)
|
1993-11-16 |
1997-02-04 |
Cameron; Robert B. |
In vitro method for producing differentiated universally compatible mature human blood cells
|
|
ES2204944T3
(es)
|
1994-03-03 |
2004-05-01 |
Alexion Pharmaceuticals, Inc. |
Genes y proteinas de fusion inhibidores del complemento terminal.
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
US6713247B1
(en)
|
1996-09-03 |
2004-03-30 |
Signal Pharmaceuticials, Inc. |
Human CNS cell lines and methods of use therefor
|
|
CA2291074C
(en)
|
1997-05-21 |
2008-04-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for enhancing transport across biological membranes
|
|
EP0893493A3
(de)
|
1997-07-21 |
2002-12-04 |
Aventis Pharma Deutschland GmbH |
Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
|
|
GB9720585D0
(en)
*
|
1997-09-26 |
1997-11-26 |
Smithkline Beecham Biolog |
Vaccine
|
|
WO1999029721A1
(en)
|
1997-12-10 |
1999-06-17 |
Washington University |
Anti-pathogen system and methods of use thereof
|
|
WO1999053023A1
(en)
|
1998-04-08 |
1999-10-21 |
Shionogi & Co., Ltd. |
Methods for isolating osteoclast precursor cells and inducing the differentiation of the same into osteoclasts
|
|
US6835567B1
(en)
*
|
1998-04-14 |
2004-12-28 |
Signal Pharmaceuticals, Inc. |
PNS cell lines and methods of use therefor
|
|
US6451558B1
(en)
|
1998-08-03 |
2002-09-17 |
Novartis Ag |
Genes in the control of hematopoiesis
|
|
US6913925B1
(en)
*
|
1998-08-12 |
2005-07-05 |
Signal Pharmaceuticals Llc |
Human mesencephalon cell lines and methods of use therefor
|
|
CA2364690A1
(en)
|
1999-02-28 |
2000-10-19 |
Washington University |
Novel transduction molecules and methods for using same
|
|
WO2000059540A1
(en)
|
1999-04-05 |
2000-10-12 |
Biocrystal Ltd. |
Assay kits and methods for immune complex-mediated activation involving shed antigens
|
|
US6358739B1
(en)
|
1999-04-12 |
2002-03-19 |
Modex Therapeutiques, S.A. |
Transiently immortalized cells
|
|
US6451601B1
(en)
*
|
1999-04-12 |
2002-09-17 |
Modex Therapeutiques, S.A. |
Transiently immortalized cells for use in gene therapy
|
|
WO2000061617A2
(en)
|
1999-04-12 |
2000-10-19 |
Modex Therapeutiques, S.A. |
Transiently immortalized cells for use in gene therapy
|
|
US7135287B1
(en)
|
1999-10-02 |
2006-11-14 |
Biosite, Inc. |
Human antibodies
|
|
US7311920B1
(en)
|
1999-10-08 |
2007-12-25 |
University Of Maryland Biotechnology Institute |
Virus coat protein/receptor chimeras and methods of use
|
|
WO2001034824A2
(en)
|
1999-11-10 |
2001-05-17 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions comprising renilla gfp
|
|
EP1103615A1
(en)
|
1999-11-25 |
2001-05-30 |
Universite De Geneve |
Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
|
|
US20010049393A1
(en)
|
1999-12-07 |
2001-12-06 |
Whitehead Institute For Biomedical Research |
Methods for defining MYC target genes and uses thereof
|
|
AU2001256746A1
(en)
|
2000-05-15 |
2001-11-26 |
Sonoko Habu |
Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
|
|
US20020155127A1
(en)
|
2000-06-02 |
2002-10-24 |
Danher Wang |
Genetic vaccine against human immunodeficiency virus
|
|
US20030072794A1
(en)
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
|
US20070248618A1
(en)
|
2004-03-16 |
2007-10-25 |
Cohen David I |
Tat-Based vaccine Compositions and Methods of Making and Using Same
|
|
WO2002024899A2
(en)
|
2000-09-25 |
2002-03-28 |
Valentis, Inc. |
Improved system for regulation of transgene expression
|
|
WO2002036738A2
(en)
|
2000-10-30 |
2002-05-10 |
Kalobios, Inc. |
Affinity maturation by competitive selection
|
|
US20040241140A1
(en)
|
2000-11-01 |
2004-12-02 |
Pavlakis George N. |
Expression vectors able to elicit improved immune response and methods of using same
|
|
DE60131676T2
(de)
|
2000-12-01 |
2008-10-30 |
Central Institute For Experimental Animals |
Verfahren zur herstellung einer maus, die für die aufnahme, differenzierung und proliferation von heterogenen zellen geeignet ist, die hierdurch hergestellte maus und ihre verwendung
|
|
WO2002057436A2
(en)
|
2001-01-19 |
2002-07-25 |
Gendel Limited |
Red blood cell from a transgenic animal as vehicle for polypeptide delivery
|
|
JP3454818B1
(ja)
*
|
2001-03-16 |
2003-10-06 |
直哉 小林 |
肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途
|
|
US7381813B2
(en)
*
|
2001-05-31 |
2008-06-03 |
Novartis Ag |
Nucleic acids encoding estrogen receptor ligand binding domain variants
|
|
MXPA04001974A
(es)
|
2001-08-31 |
2004-07-16 |
Avidex Ltd |
Receptor de celula t soluble.
|
|
CN1408850A
(zh)
*
|
2001-09-18 |
2003-04-09 |
王虹 |
人血树突状细胞永生化技术
|
|
CN100506978C
(zh)
|
2001-09-21 |
2009-07-01 |
中国人民解放军军事医学科学院野战输血研究所 |
一种新的造血干/祖细胞的富集方法及其体外定向诱导分化
|
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
|
WO2003039462A2
(en)
|
2001-11-02 |
2003-05-15 |
Tanox, Inc. |
B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
|
|
EP1321034A1
(en)
*
|
2001-12-21 |
2003-06-25 |
Pfizer Products Inc. |
Disruption of the phosphodieterase 10 gene
|
|
AU2003202908A1
(en)
|
2002-01-03 |
2003-07-24 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
EP1572933A4
(en)
|
2002-02-13 |
2007-09-05 |
Univ Duke |
MODULATION OF THE IMMUNE RESPONSE BY POLYPEPTIDES AS AN ANSWER TO NONPEPTIDIC BINDING STRENGTH
|
|
CN1240439C
(zh)
|
2002-03-28 |
2006-02-08 |
南京凯基生物科技发展有限公司 |
肿瘤基因开关药物
|
|
US7211191B2
(en)
|
2004-09-30 |
2007-05-01 |
Thermogenesis Corp. |
Blood component separation method and apparatus
|
|
AU2003228517B2
(en)
*
|
2002-04-16 |
2007-06-21 |
Dana-Farber Cancer Institute, Inc. |
Cancer models
|
|
GB2387599B
(en)
|
2002-04-17 |
2005-08-10 |
Jason Peter Brown |
Methods for producing antibodies
|
|
US7097841B2
(en)
|
2002-05-10 |
2006-08-29 |
New Century Pharmaceuticals, Inc. |
Ferritin fusion proteins for use in vaccines and other applications
|
|
KR20100063126A
(ko)
*
|
2002-05-16 |
2010-06-10 |
버베리안 노딕 에이/에스 |
Ｈｉｖ 조절/부속 단백질의 융합 단백질
|
|
AU2003237259B2
(en)
*
|
2002-05-29 |
2008-01-24 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
NZ539225A
(en)
|
2002-10-09 |
2006-09-29 |
Avidex Ltd |
Single chain recombinant T cell receptors
|
|
ATE350480T1
(de)
|
2002-10-11 |
2007-01-15 |
Imvision Gmbh |
Moduläre antigen-transporter moleküle (mat- moleküle) zur modulierung von immunreaktionen, zugehörige konstrukte, verfahren und verwendungen
|
|
WO2004035535A2
(en)
|
2002-10-15 |
2004-04-29 |
Yeda Research And Development Co. Ltd. |
Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
|
|
AU2003276403B2
(en)
|
2002-11-09 |
2010-04-15 |
Adaptimmune Limited |
T cell receptor display
|
|
US20060247192A1
(en)
|
2002-12-05 |
2006-11-02 |
Jenkinson John D |
Control of apoptosis
|
|
GB0304068D0
(en)
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
US7482016B2
(en)
|
2003-03-19 |
2009-01-27 |
The J. David Gladstone Institutes |
Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
|
|
DE60334250D1
(de)
|
2003-05-08 |
2010-10-28 |
Life Technologies Corp |
Erzeugung und isolierung antigenspezifischer t-zellen
|
|
WO2005014785A2
(en)
|
2003-06-18 |
2005-02-17 |
The George Washington University |
Conditionally-immortalized hematopoietic progenitor cell lines
|
|
CA2529752A1
(en)
|
2003-06-20 |
2005-09-15 |
The Regents Of The University Of California |
Polypeptide transduction and fusogenic peptides
|
|
IL161903A0
(en)
|
2003-07-17 |
2005-11-20 |
Gamida Cell Ltd |
Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
|
|
US7705049B2
(en)
|
2004-01-21 |
2010-04-27 |
New York University |
Methods for treating non-melanoma cancers with PABA
|
|
JP2005232148A
(ja)
*
|
2004-02-03 |
2005-09-02 |
Technion Research & Development Foundation Ltd |
神経保護剤としてプロパルギルアミンの使用
|
|
JP4773434B2
(ja)
|
2004-05-19 |
2011-09-14 |
イムノコア リミテッド |
高親和性ｎｙ−ｅｓｏｔ細胞受容体
|
|
EP1756278B1
(en)
|
2004-05-19 |
2008-09-17 |
MediGene Ltd. |
Method of improving t cell receptors
|
|
JP5563194B2
(ja)
|
2004-06-29 |
2014-07-30 |
イムノコア リミテッド |
改変ｔ細胞レセプターを発現する細胞
|
|
WO2006137836A2
(en)
|
2004-08-17 |
2006-12-28 |
Research Development Foundation |
Bacterial vector systems
|
|
GB0420963D0
(en)
|
2004-09-21 |
2004-10-20 |
Reneuron Ltd |
Hepatocyte
|
|
WO2006045064A2
(en)
*
|
2004-10-20 |
2006-04-27 |
Whitehead Institute For Biomedical Research |
Cultured hematopoietic stem cells and method for expansion and analysis thereof
|
|
US8795650B2
(en)
|
2004-12-09 |
2014-08-05 |
The Regents Of The University Of California |
Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
|
|
US20060156422A1
(en)
|
2005-01-10 |
2006-07-13 |
Medical Research Council |
Methods and compositions for the generation of antibodies
|
|
WO2006104978A2
(en)
|
2005-03-25 |
2006-10-05 |
Curagen Corporation |
Antibodies against the tenascin major antigens
|
|
EP1876894A1
(en)
|
2005-04-26 |
2008-01-16 |
The Board of Trustees of the University of Illinois |
Nucleoside compounds and methods of use thereof
|
|
WO2006125962A2
(en)
|
2005-05-25 |
2006-11-30 |
Medigene Limited |
T cell receptors which specifically bind to vygfvracl-hla-a24
|
|
WO2007025286A2
(en)
|
2005-08-26 |
2007-03-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Therapy procedure for drug delivery for trigeminal pain
|
|
US20070047583A1
(en)
|
2005-08-29 |
2007-03-01 |
Siemens Aktiengesellschaft |
Method for using a short address in a packet header
|
|
IN2014DN06624A
(enExample)
|
2005-10-18 |
2015-07-10 |
Univ Colorado |
|
|
WO2007056326A2
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
|
EP1792627A1
(en)
|
2005-12-05 |
2007-06-06 |
ImVisioN AG |
Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
|
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
WO2008038002A2
(en)
|
2006-09-29 |
2008-04-03 |
Medigene Limited |
T cell therapies
|
|
CN101688228B
(zh)
|
2007-03-13 |
2014-12-24 |
国家犾太健康中心 |
抗体产生的方法
|
|
EP2214670A2
(en)
|
2007-11-02 |
2010-08-11 |
Taiga Biotechnologies, Inc. |
Compounds for treating abnormal cellular proliferation
|
|
JP5951254B2
(ja)
|
2008-03-17 |
2016-07-13 |
ザ スクリプス リサーチ インスティテュート |
人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
|
|
US8986702B2
(en)
|
2008-05-16 |
2015-03-24 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
|
WO2009149956A2
(en)
|
2008-06-13 |
2009-12-17 |
Life & Brain Gmbh |
Fusion protein and use thereof
|
|
CA2731767C
(en)
|
2008-07-21 |
2016-12-06 |
Taiga Biotechnologies, Inc. |
Differentiated anucleated cells and method for preparing the same
|
|
DK2966084T3
(en)
|
2008-08-28 |
2018-08-06 |
Taiga Biotechnologies Inc |
MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
|
|
EP3031907B1
(en)
|
2008-11-06 |
2021-01-06 |
Indiana University Research and Technology Corporation |
Materials and methods to enhance hematopoietic stem cells engraftment procedures
|
|
CN102272153B
(zh)
|
2008-11-24 |
2015-04-15 |
德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 |
高亲和力t细胞受体及其应用
|
|
WO2011100477A2
(en)
|
2010-02-10 |
2011-08-18 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
|
US20120107317A1
(en)
|
2010-10-27 |
2012-05-03 |
The University Of Hong Kong |
Use of cytoplasmic c-myc for regulating immune responses
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
CA3114877C
(en)
|
2011-09-15 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
|
CN107557334B
(zh)
|
2012-05-03 |
2021-06-25 |
弗雷德哈钦森癌症研究中心 |
增强亲和力的t细胞受体及其制备方法
|
|
DE102012209673A1
(de)
|
2012-06-08 |
2013-12-24 |
Artcline Gmbh |
Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation
|
|
AU2013292330B2
(en)
|
2012-07-20 |
2018-07-12 |
Htyr Acquisition Llc |
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
|
|
EP2877489A4
(en)
|
2012-07-27 |
2016-04-13 |
Univ Illinois |
MANIPULATION OF T-CELL RECEPTORS
|
|
US20140109246A1
(en)
|
2012-09-24 |
2014-04-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
|
|
GB2508414A
(en)
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
US20160010058A1
(en)
|
2013-03-01 |
2016-01-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
AU2013379773B2
(en)
|
2013-03-01 |
2018-04-19 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor reactive T cells from peripheral blood
|
|
US9365825B2
(en)
|
2013-03-11 |
2016-06-14 |
Taiga Biotechnologies, Inc. |
Expansion of adult stem cells in vitro
|
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
|
WO2015164740A1
(en)
|
2014-04-24 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
AU2015371265B2
(en)
|
2014-12-24 |
2021-06-03 |
Neximmune, Inc |
Nanoparticle compositions and methods for immunotherapy
|
|
TWI756199B
(zh)
|
2016-01-15 |
2022-03-01 |
美商伯克利之光生命科技公司 |
製造患者專ㄧ性抗癌治療劑之方法及使用該治療劑之治療方法
|
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|